There have been dramatic changes worldwide in the attitudes toward and consumption of recreational and medical cannabis. Cannabinoid receptors, which mediate the actions of cannabis, are abundantly expressed in brain regions known to mediate neural processes underlying reward, cognition, emotional regulation and stress responsivity relevant to addiction vulnerability. Despite debates regarding potential pathological consequences of cannabis use, cannabis use disorder is a clinical diagnosis with high prevalence in the general population and that often has its genesis in adolescence and in vulnerable individuals associated with psychiatric comorbidity, genetic and environmental factors. Integrated information from human and animal studies is beginning to expand insights regarding neurobiological systems associated with cannabis use disorder, which often share common neural characteristics with other substance use disorders, that could inform prevention and treatment strategies.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
UN Office on Drugs and Crime. World Drug Report 3: Market Analysis of Plant-Based Drugs: Opiates, Cocaine, Cannabis. (UNODC Research, 2017).
Hasin, D. S. et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry 72, 1235–1242 (2015).
Martins, S. S. et al. Changes in US lifetime heroin use and heroin use disorder: prevalence from the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 74, 445–455 (2017).
Kerridge, B. T. et al. Changes in the prevalence and correlates of cocaine use and cocaine use disorder in the United States, 2001-2002 and 2012-2013. Addict. Behav. 90, 250–257 (2019).
Nutt, D. J., King, L. A. & Phillips, L. D., Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet 376, 1558–1565 (2010).
Hasin, D. S. et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am. J. Psychiatry 173, 588–599 (2016).
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O. & Appendino, G. Phytocannabinoids: a unified critical inventory. Nat. Prod. Rep. 33, 1357–1392 (2016).
ElSohly, M. A. et al. Potency trends of Δ9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J. Forensic Sci. 45, 24–30 (2000).
Chandra, S. et al. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur. Arch. Psychiatry Clin. Neurosci. 269, 5–15 (2019).
Mechoulam, R., Hanuš, L. O., Pertwee, R. & Howlett, A. C. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 15, 757–764 (2014).
Mechoulam, R. & Parker, L. A. The endocannabinoid system and the brain. Annu. Rev. Psychol. 64, 21–47 (2013).
Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 1932–1936 (1990).
Busquets-Garcia, A., Bains, J. & Marsicano, G. CB1 receptor signaling in the brain: extracting specificity from ubiquity. Neuropsychopharmacology 43, 4–20 (2018).
Xi, Z. X. et al. Brain cannabinoid CB2 receptors modulate cocaine’s actions in mice. Nat. Neurosci. 14, 1160–1166 (2011).
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th ed (American Psychiatric Association, 2013).
Feingold, D., Fox, J., Rehm, J. & Lev-Ran, S. Natural outcome of cannabis use disorder: a 3-year longitudinal follow-up. Addiction 110, 1963–1974 (2015).
Verweij, K. J. et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction 105, 417–430 (2010).
Lynskey, M. T. et al. An Australian twin study of cannabis and other illicit drug use and misuse, and other psychopathology. Twin Res. Hum. Genet. 15, 631–641 (2012).
Gillespie, N. A., Neale, M. C. & Kendler, K. S. Pathways to cannabis abuse: a multi-stage model from cannabis availability, cannabis initiation and progression to abuse. Addiction 104, 430–438 (2009).
Agrawal, A. et al. Genome-wide association study identifies a novel locus for cannabis dependence. Mol. Psychiatry 23, 1293–1302 (2018).
Demontis, D. et al. Genome-wide association study implicates CHRNA2 in cannabis use disorder. Nat. Neurosci. 22, 1066–1074 (2019).
Yang, J. et al. The contribution of rare and common variants in 30 genes to risk nicotine dependence. Mol. Psychiatry 20, 1467–1478 (2015).
McKay, J. D. et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat. Genet. 49, 1126–1132 (2017).
Pasman, J. A. et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat. Neurosci. 21, 1161–1170 (2018).
Sherva, R. et al. Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks. JAMA Psychiatry 73, 472–480 (2016).
Di Forti, M. et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 6, 427–436 (2019).
Radhakrishnan, R., Wilkinson, S. T. & D’Souza, D. C. Gone to pot - a review of the association between cannabis and psychosis. Front. Psychiatry 5, 54 (2014).
Wittchen, H. U. et al. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend. 88(Suppl 1), S60–S70 (2007).
Blanco, C. et al. Cannabis use and risk of psychiatric disorders: prospective evidence from a US national longitudinal study. JAMA Psychiatry 73, 388–395 (2016).
Emery, N. N. & Simons, J. S. A reinforcement sensitivity model of affective and behavioral dysregulation in marijuana use and associated problems. Exp. Clin. Psychopharmacol. 25, 281–294 (2017).
Ridenour, T. A. et al. Neurobehavior disinhibition, parental substance use disorder, neighborhood quality and development of cannabis use disorder in boys. Drug Alcohol Depend. 102, 71–77 (2009).
Hines, L. A. et al. Overlap of heritable influences between cannabis use disorder, frequency of use and opportunity to use cannabis: trivariate twin modelling and implications for genetic design. Psychol. Med. 48, 2786–2793 (2018).
Rogosch, F. A., Oshri, A. & Cicchetti, D. From child maltreatment to adolescent cannabis abuse and dependence: a developmental cascade model. Dev. Psychopathol. 22, 883–897 (2010).
Stinson, F. S., Ruan, W. J., Pickering, R. & Grant, B. F. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol. Med. 36, 1447–1460 (2006).
Haberstick, B. C. et al. Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend. 136, 158–161 (2014).
Khan, S. S. et al. Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug Alcohol Depend. 130, 101–108 (2013).
Hirvonen, J. et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol. Psychiatry 17, 642–649 (2012).
Ceccarini, J. et al. [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict. Biol. 20, 357–367 (2015).
D’Souza, D. C. et al. Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 1, 60–67 (2016).
Koob, G. F. & Volkow, N. D. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3, 760–773 (2016).
Villares, J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 145, 323–334 (2007).
Boileau, I. et al. Fatty acid amide hydrolase binding in brain of cannabis users: imaging with the novel radiotracer [11C]CURB. Biol. Psychiatry 80, 691–701 (2016).
Bossong, M. G. et al. Δ9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34, 759–766 (2009).
Thiruchselvam, T., Malik, S. & Le Foll, B. A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate. Am. J. Drug Alcohol Abuse 43, 197–214 (2017).
Urban, N. B. et al. Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol. Psychiatry 71, 677–683 (2012).
van de Giessen, E. et al. Deficits in striatal dopamine release in cannabis dependence. Mol. Psychiatry 22, 68–75 (2017).
Volkow, N. D. et al. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc. Natl Acad. Sci. USA 111, E3149–E3156 (2014).
Bloomfield, M. A. et al. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol. Psychiatry 75, 470–478 (2014).
Bloomfield, M. A., Morgan, C. J., Kapur, S., Curran, H. V. & Howes, O. D. The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology (Berl.) 231, 2251–2259 (2014).
Leroy, C. et al. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study. Addict. Biol. 17, 981–990 (2012).
Volkow, N. D., Fowler, J. S., Wang, G. J., Baler, R. & Telang, F. Imaging dopamine’s role in drug abuse and addiction. Neuropharmacology 56(Suppl 1), 3–8 (2009).
Kalivas, P. W. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 10, 561–572 (2009).
Katona, I. Cannabis and endocannabinoid signaling in epilepsy. Handb. Exp. Pharmacol. 231, 285–316 (2015).
Colizzi, M., McGuire, P., Pertwee, R. G. & Bhattacharyya, S. Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. Neurosci. Biobehav. Rev. 64, 359–381 (2016).
Colizzi, M. et al. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. Mol. Psychiatry https://doi.org/10.1038/s41380-019-0374-8 (2019).
Muetzel, R. L. et al. In vivo 1H magnetic resonance spectroscopy in young-adult daily marijuana users. Neuroimage Clin. 2, 581–589 (2013).
Prescot, A. P., Locatelli, A. E., Renshaw, P. F. & Yurgelun-Todd, D. A. Neurochemical alterations in adolescent chronic marijuana smokers: a proton MRS study. Neuroimage 57, 69–75 (2011).
Mon, A., Durazzo, T. C. & Meyerhoff, D. J. Glutamate, GABA, and other cortical metabolite concentrations during early abstinence from alcohol and their associations with neurocognitive changes. Drug Alcohol Depend. 125, 27–36 (2012).
Yang, S. et al. Lower glutamate levels in rostral anterior cingulate of chronic cocaine users - A (1)H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategy. Psychiatry Res. 174, 171–176 (2009).
Bolla, K. I., Eldreth, D. A., Matochik, J. A. & Cadet, J. L. Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 26, 480–492 (2005).
Izquierdo, A. Functional heterogeneity within rat orbitofrontal cortex in reward learning and decision making. J. Neurosci. 37, 10529–10540 (2017).
Guttman, Z., Moeller, S. J. & London, E. D. Neural underpinnings of maladaptive decision-making in addictions. Pharmacol. Biochem. Behav. 164, 84–98 (2018).
Battistella, G. et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 39, 2041–2048 (2014).
Chye, Y. et al. Orbitofrontal and caudate volumes in cannabis users: a multi-site mega-analysis comparing dependent versus non-dependent users. Psychopharmacology (Berl.) 234, 1985–1995 (2017).
Cheetham, A. et al. Orbitofrontal volumes in early adolescence predict initiation of cannabis use: a 4-year longitudinal and prospective study. Biol. Psychiatry 71, 684–692 (2012).
Chye, Y. et al. Cannabis-related hippocampal volumetric abnormalities specific to subregions in dependent users. Psychopharmacology (Berl.) 234, 2149–2157 (2017).
Schacht, J. P., Hutchison, K. E. & Filbey, F. M. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology 37, 2368–2376 (2012).
French, L. et al. Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiatry 72, 1002–1011 (2015).
Cousijn, J. et al. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. Neuroimage 59, 3845–3851 (2012).
Koenders, L. et al. Grey matter changes associated with heavy cannabis use: a longitudinal sMRI study. PLoS One 11, e0152482 (2016).
Pagliaccio, D. et al. Shared predisposition in the association between cannabis use and subcortical brain structure. JAMA Psychiatry 72, 994–1001 (2015).
Scallet, A. C. et al. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res. 436, 193–198 (1987).
Miller, M. L. et al. Adolescent exposure to Δ9-tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons. Mol. Psychiatry 24, 588–600 (2018).
Zahr, N. M. & Pfefferbaum, A. Alcohol’s effects on the brain: neuroimaging results in humans and animal models. Alcohol Res. 38, 183–206 (2017).
Wollman, S. C. et al. Gray matter abnormalities in opioid-dependent patients: A neuroimaging meta-analysis. Am. J. Drug Alcohol Abuse 43, 505–517 (2017).
Mackey, S. et al. Mega-analysis of gray matter volume in substance dependence: general and substance-specific regional effects. Am. J. Psychiatry 176, 119–128 (2019).
Medina, K. L., Nagel, B. J. & Tapert, S. F. Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiatry Res. 182, 152–159 (2010).
Schmahmann, J. D. The cerebellum and cognition. Neurosci. Lett. 688, 62–75 (2019).
Nader, D. A. & Sanchez, Z. M. Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults. Am. J. Drug Alcohol Abuse 44, 4–18 (2018).
DeWitt, S. J., Ketcherside, A., McQueeny, T. M., Dunlop, J. P. & Filbey, F. M. The hyper-sentient addict: an exteroception model of addiction. Am. J. Drug Alcohol Abuse 41, 374–381 (2015).
Pujol, J. et al. Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. J. Psychiatr. Res. 51, 68–78 (2014).
Wetherill, R. R. et al. Cannabis, cigarettes, and their co-occurring use: Disentangling differences in default mode network functional connectivity. Drug Alcohol Depend. 153, 116–123 (2015).
Mak, L. E. et al. The default mode network in healthy individuals: a systematic review and meta-analysis. Brain Connect. 7, 25–33 (2017).
Blanco-Hinojo, L. et al. Attenuated frontal and sensory inputs to the basal ganglia in cannabis users. Addict. Biol. 22, 1036–1047 (2017).
Kober, H., DeVito, E. E., DeLeone, C. M., Carroll, K. M. & Potenza, M. N. Cannabis abstinence during treatment and one-year follow-up: relationship to neural activity in men. Neuropsychopharmacology 39, 2288–2298 (2014).
Chang, L., Yakupov, R., Cloak, C. & Ernst, T. Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain 129, 1096–1112 (2006).
Broyd, S. J., van Hell, H. H., Beale, C., Yücel, M. & Solowij, N. Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol. Psychiatry 79, 557–567 (2016).
Kanayama, G., Rogowska, J., Pope, H. G., Gruber, S. A. & Yurgelun-Todd, D. A. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology (Berl.) 176, 239–247 (2004).
Smith, A. M., Longo, C. A., Fried, P. A., Hogan, M. J. & Cameron, I. Effects of marijuana on visuospatial working memory: an fMRI study in young adults. Psychopharmacology (Berl.) 210, 429–438 (2010).
Sagar, K. A. & Gruber, S. A. Interactions between recreational cannabis use and cognitive function: lessons from functional magnetic resonance imaging. Ann. NY Acad. Sci. 1451, 42–70 (2019).
Schweinsburg, A. D. et al. The influence of recency of use on fMRI response during spatial working memory in adolescent marijuana users. J. Psychoactive Drugs 42, 401–412 (2010).
Padula, C. B., Schweinsburg, A. D. & Tapert, S. F. Spatial working memory performance and fMRI activation interaction in abstinent adolescent marijuana users. Psychol. Addict. Behav. 21, 478–487 (2007).
Cousijn, J. et al. Neural responses associated with cue-reactivity in frequent cannabis users. Addict. Biol. 18, 570–580 (2013).
Filbey, F. M., Schacht, J. P., Myers, U. S., Chavez, R. S. & Hutchison, K. E. Marijuana craving in the brain. Proc. Natl Acad. Sci. USA 106, 13016–13021 (2009).
Filbey, F. M. et al. fMRI study of neural sensitization to hedonic stimuli in long-term, daily cannabis users. Hum. Brain Mapp. 37, 3431–3443 (2016).
Filbey, F. M., Schacht, J. P., Myers, U. S., Chavez, R. S. & Hutchison, K. E. Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology 35, 967–975 (2010).
Zimmermann, K. et al. Altered orbitofrontal activity and dorsal striatal connectivity during emotion processing in dependent marijuana users after 28 days of abstinence. Psychopharmacology (Berl.) 235, 849–859 (2018).
Wesley, M. J., Lile, J. A., Hanlon, C. A. & Porrino, L. J. Abnormal medial prefrontal cortex activity in heavy cannabis users during conscious emotional evaluation. Psychopharmacology (Berl.) 233, 1035–1044 (2016).
Breivogel, C. S. et al. Chronic Δ9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J. Neurochem. 73, 2447–2459 (1999).
Burston, J. J., Wiley, J. L., Craig, A. A., Selley, D. E. & Sim-Selley, L. J. Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats following repeated Δ9-tetrahydrocannabinol exposure. Br. J. Pharmacol. 161, 103–112 (2010).
Rubino, T. et al. Chronic Δ9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33, 2760–2771 (2008).
Sim-Selley, L. J. et al. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol. Pharmacol. 70, 986–996 (2006).
Fan, N., Yang, H., Zhang, J. & Chen, C. Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Δ9-THC exposure-impaired hippocampal synaptic plasticity. J. Neurochem. 112, 691–702 (2010).
Wang, H. & Zhang, M. The role of Ca2+-stimulated adenylyl cyclases in bidirectional synaptic plasticity and brain function. Rev. Neurosci. 23, 67–78 (2012).
Barco, A. & Marie, H. Genetic approaches to investigate the role of CREB in neuronal plasticity and memory. Mol. Neurobiol. 44, 330–349 (2011).
Steel, R. W., Miller, J. H., Sim, D. A. & Day, D. J. Delta-9-tetrahydrocannabinol disrupts hippocampal neuroplasticity and neurogenesis in trained, but not untrained adolescent Sprague-Dawley rats. Brain Res. 1548, 12–19 (2014).
Kittler, J. T. et al. Large-scale analysis of gene expression changes during acute and chronic exposure to Δ9-THC in rats. Physiol. Genomics 3, 175–185 (2000).
Grigorenko, E. et al. Assessment of cannabinoid induced gene changes: tolerance and neuroprotection. Chem. Phys. Lipids 121, 257–266 (2002).
Tantra, M. et al. St8sia2 deficiency plus juvenile cannabis exposure in mice synergistically affect higher cognition in adulthood. Behav. Brain Res. 275, 166–175 (2014).
Stringer, S. et al. Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. Transl. Psychiatry 6, e769 (2016).
Skosnik, P. D., Cortes-Briones, J. A. & Hajós, M. It’s all in the rhythm: the role of cannabinoids in neural oscillations and psychosis. Biol. Psychiatry 79, 568–577 (2016).
Raver, S. M. & Keller, A. Permanent suppression of cortical oscillations in mice after adolescent exposure to cannabinoids: receptor mechanisms. Neuropharmacology 86, 161–173 (2014).
Hajós, M., Hoffmann, W. E. & Kocsis, B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol. Psychiatry 63, 1075–1083 (2008).
Hwang, E.K. & Lupica, C.R. Altered corticolimbic control of the nucleus accumbens by long-term Δ9-tetrahydrocannabinol exposure. Biol. Psychiatry S0006-3223(19)31559-8 (2019).
Morel, L. J., Giros, B. & Daugé, V. Adolescent exposure to chronic delta-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats. Neuropsychopharmacology 34, 2469–2476 (2009).
Stopponi, S. et al. Chronic THC during adolescence increases the vulnerability to stress-induced relapse to heroin seeking in adult rats. Eur. Neuropsychopharmacol. 24, 1037–1045 (2014).
Solinas, M., Panlilio, L. V. & Goldberg, S. R. Exposure to Δ-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin’s reinforcing efficacy: a self-administration study in rats. Neuropsychopharmacology 29, 1301–1311 (2004).
Hurd, Y. L., Michaelides, M., Miller, M. L. & Jutras-Aswad, D. Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology 76(Pt B), 416–424 (2014).
Blanco, C., Flórez-Salamanca, L., Secades-Villa, R., Wang, S. & Hasin, D. S. Predictors of initiation of nicotine, alcohol, cannabis, and cocaine use: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Am. J. Addict. 27, 477–484 (2018).
Panlilio, L. V., Zanettini, C., Barnes, C., Solinas, M. & Goldberg, S. R. Prior exposure to THC increases the addictive effects of nicotine in rats. Neuropsychopharmacology 38, 1198–1208 (2013).
Hillard, C. J., Beatka, M. & Sarvaideo, J. Endocannabinoid signaling and the hypothalamic-pituitary-adrenal axis. Compr. Physiol. 7, 1–15 (2016).
Harte-Hargrove, L. C. & Dow-Edwards, D. L. Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety. Behav. Brain Res. 231, 48–59 (2012).
O’Shea, M., Singh, M. E., McGregor, I. S. & Mallet, P. E. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J. Psychopharmacol. 18, 502–508 (2004).
Barrus, D. G., Lefever, T. W. & Wiley, J. L. Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats. Neuropharmacology 137, 133–140 (2018).
Nguyen, J. D. et al. Inhaled delivery of Δ(9)-tetrahydrocannabinol (THC) to rats by e-cigarette vapor technology. Neuropharmacology 109, 112–120 (2016).
Bruijnzeel, A. W. et al. Behavioral characterization of the effects of cannabis smoke and anandamide in rats. PLoS One 11, e0153327 (2016).
Månsson, K. N. et al. Neuroplasticity in response to cognitive behavior therapy for social anxiety disorder. Transl. Psychiatry 6, e727 (2016).
Yang, Z. et al. Cognitive behavioral therapy is associated with enhanced cognitive control network activity in major depression and posttraumatic stress disorder. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 3, 311–319 (2018).
MinlanYuan et al. Cerebellar neural circuits involving executive control network predict response to group cognitive behavior therapy in social anxiety disorder. Cerebellum 16, 673–682 (2017).
Morgan, C. J., Schafer, G., Freeman, T. P. & Curran, H. V. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br. J. Psychiatry 197, 285–290 (2010).
Bergamaschi, M. M. et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36, 1219–1226 (2011).
Crippa, J. A. et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25, 121–130 (2011).
Murphy, M. et al. Chronic adolescent Δ9-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment. Cannabis Cannabinoid Res. 2, 235–246 (2017).
Zuardi, A. W., Shirakawa, I., Finkelfarb, E. & Karniol, I. G. Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects. Psychopharmacology (Berl.) 76, 245–250 (1982).
Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V. & Hurd, Y. L. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J. Neurosci. 29, 14764–14769 (2009).
Grimm, O. et al. Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity. Eur. Neuropsychopharmacol. 28, 841–849 (2018).
Beale, C. et al. Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users. Cannabis Cannabinoid Res. 3, 94–107 (2018).
Haney, M. et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology 41, 1974–1982 (2016).
White, T. et al. Paediatric population neuroimaging and the Generation R Study: the second wave. Eur. J. Epidemiol. 33, 99–125 (2018).
Szutorisz, H. & Hurd, Y. L. Epigenetic effects of cannabis exposure. Biol. Psychiatry 79, 586–594 (2016).
Filbey, F. M. et al. Long-term effects of marijuana use on the brain. Proc. Natl Acad. Sci. USA 111, 16913–16918 (2014).
De Bellis, M. D. et al. Neural mechanisms of risky decision-making and reward response in adolescent onset cannabis use disorder. Drug Alcohol Depend. 133, 134–145 (2013).
Nestor, L., Hester, R. & Garavan, H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage 49, 1133–1143 (2010).
Yücel, M. et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 65, 694–701 (2008).
Charboneau, E. J. et al. Cannabis cue-induced brain activation correlates with drug craving in limbic and visual salience regions: preliminary results. Psychiatry Res. 214, 122–131 (2013).
Goldman, M. et al. Reward-related brain response and craving correlates of marijuana cue exposure: a preliminary study in treatment-seeking marijuana-dependent subjects. J. Addict. Med. 7, 8–16 (2013).
Brezing, C. A. & Levin, F. R. The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology 43, 173–194 (2018).
Morgan, C. J., Freeman, T. P., Schafer, G. L. & Curran, H. V. Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35, 1879–1885 (2010).
D’Souza, D. C. et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry 6, 35–45 (2019).
Kawamura, Y. et al. The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J. Neurosci. 26, 2991–3001 (2006).
This work was supported by a grant from the US National Institutes of Health (NIH) DA030359.
The authors declare no competing interests.
Peer review information Nature Neuroscience thanks Rafael Maldonado and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ferland, JM.N., Hurd, Y.L. Deconstructing the neurobiology of cannabis use disorder. Nat Neurosci 23, 600–610 (2020). https://doi.org/10.1038/s41593-020-0611-0
Addiction Science & Clinical Practice (2021)
Cannabinoid receptor activation acutely increases synaptic vesicle numbers by activating synapsins in human synapses
Molecular Psychiatry (2021)
Nature Reviews Neuroscience (2021)
Current Behavioral Neuroscience Reports (2020)